| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 14, 2025 4:15 P.M. |
| Form: | F-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/8/2025 | $72.00 | Buy | BTIG Research |
| 5/13/2025 | Buy | TD Cowen | |
| 5/7/2025 | $80.00 | Buy | Chardan Capital Markets |
| 1/23/2025 | $93.00 | Overweight | Piper Sandler |
| 1/10/2025 | Overweight | Cantor Fitzgerald | |
| 1/10/2025 | $85.00 | Buy | H.C. Wainwright |
| 11/26/2024 | $75.00 | Outperform | Robert W. Baird |
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
3 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the "Common Shares") at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the "Offering"). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by Bright Minds. The Company intends to use the net proceeds
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces the pricing of its previously announced public offering of 1,945,000 common shares in the capital of the Company (the "Common Shares") at a price of $90.00 per Common Share for anticipated gross proceeds of $175,050,000 (the "Offering"). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities being sold in this Offering are being offered by Bright Minds. The closing
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces the launch of a public offering of common shares in the capital of the Company (the "Common Shares") and, in lieu of Common Shares to investors that so choose, pre-funded warrants (the "Pre-Funded Warrants") to purchase Common Shares, for aggregate gross proceeds of US$100 million (the "Offering"). In connection with the Offering, the Company intends to grant to the underwriters, a 30-day option to purchase up to an additional 15% of the Common Shares issued in the Offering. The Company intends to use the net proceeds from the Offering to fund futu
SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
BTIG Research initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $72.00
TD Cowen initiated coverage of Bright Minds Biosciences with a rating of Buy
Chardan Capital Markets initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $80.00
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13D/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an
-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 -- VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for a
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board. "In his short tenure on the Board, Doug's scientific, clinical, and medical experience has proven invaluable in supporting our efforts to develop the next generation of safe and efficacious drugs for challenging br
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% increase in REM sleep with no change in total sleep durationCompany has initiated preparations for global registrational trials in both DEE and Absence Seizure patientsBright Minds to hold conference call and live webcast at 8AM ET today NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical
– Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy. Webcast Information The Bright Minds virtual event will be webcast live and a replay will be available after th
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape.